63rd ASH Annual Meeting and Exposition: 902. Health Services Research

Oral and Poster Abstracts
Poster

Hall B5, Level 1, Building B (Georgia World Congress Center)

Impact of Treating Facility on Overall Survival and Treatment in Multiple Myeloma (MM) Using National Cancer Database (NCDB)

Kimberley Doucette, MD¹, Allison Taylor, MD, MS², Bryan Chan, MPH³^*, Xiaoyang Ma, MS³^*, Jaeil Ahn, PhD⁴^*, David H. Vesole, MD, PhD⁵ and Catherine Lai, MD, MPH⁶

¹Lombardi Comprehensive Cancer Center, MedStar Georgetown University Hospital, Washington, DC
²Internal Medicine, Duke University School of Medicine, Durham
³Lombardi Comprehensive Cancer Center, Medstar Georgetown University Hospital, Washington, DC
⁴Georgetown University, Department of Biostatistics, Bioinformatics, and Biomathematics, Washington D.C.
⁵John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
⁶Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC

2997

Virtual Versus in-Person Frailty Assessments in Older Adults with Hematologic Malignancies

Clark Dumontier, MD, MPH^1,2,3^*, Tim Jaung, MS⁴^*, Nupur E. Bahl, BS⁴^*, Emily S. Magnavita, MPH⁴^*, Brad Manor, PhD^3,5^*, Marcia Testa, MPH, Mphil, PhD⁶^*, Dae Kim, MD, ScD, MPH^3,5^*, Tammy T. Hshieh, MD, MPH^2,3,4^*, Jane Driver, MD, MPH^2,3,7^* and Gregory A. Abel, MD, MPH^4,8

¹New England Geriatric Research Education and Clinical Center, Boston, MA
²Brigham and Women's Hospital, Boston, MA
³Harvard Medical School, Boston, MA
⁴Dana-Farber Cancer Institute, Boston, MA
⁵Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, MA
⁶Harvard T.H. Chan School of Public Health, Boston, MA
⁷New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, MA
⁸Center for Bioethics, Harvard Medical School, Boston, MA

2998

How Important Are in-Person Clinic Visits during Maintenance Therapy for Pediatric Acute Lymphoblastic Leukemia?

Ron Rabinowicz, MD¹^*, Johann K Hitzler, MD² and Angela Punnett, MD³^*

¹The Hospital for Sick Children, Toronto, ON, Canada
²Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
³Hospital for Sick Children, Toronto, ON, Canada

2999

Time and Personnel Costs Associated with Adverse Event (AE) Management Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Acalabrutinib, Ibrutinib, or Venetoclax

Hetalkumari Patel, PharmD¹^*, Svea K. Wahlstrom, VMD, MS²^*, Maral DerSarkissian, PhD³^*, Colin Kunzweiler, PhD, MS⁴^*, Felicia Castriota, MPH, PhD⁴^*, Rose Chang, MSPH, MS, ScD⁴^*, Hoi Ching Cheung, BA⁴^*, Yuqian Gu, MS³^*, Helen Guo, BA³^*, Mei Sheng Duh, ScD, MPH⁴ and Kellie J. Ryan, MPH²^*

¹UT Southwestern Medical Center, Dallas, TX
²AstraZeneca, Gaithersburg, MD
³Analysis Group, Inc., Los Angeles, CA
⁴Analysis Group, Inc., Boston, MA

3000

Improving Outcomes for Patients with Multiple Myeloma through the Optimization of Treatment Sequences

Maria Teresa Petrucci, MD¹, João Mendes²^*, Jennifer H. Boer³^*, Gabriele Casamassima⁴^*, Anna Willis⁵^*, Astrid Ottosson Wadlund⁶^*, Suzette Matthijsse³^* and Patrizio Armeni⁷^*

¹Hematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy
²Janssen Cilag, Porto Salvo, Portugal
³BresMed, Utrecht, Netherlands
⁴Janssen Cilag Spa, Milan, NC, ITA
⁵BresMed, Sheffiel, United Kingdom
⁶Janssen Cilag AB, Solna, Sweden
⁷Cergas (Centre for Research on Health and Social Care Management), SDA Bocconi School of Management,, Milan, Italy

3001

Current Clinical Practice and Decision-Making in Multiple Myeloma Treatment in the United States of America: A Real-World Survey

Amanda Ribbands¹^*, Boris Gorsh, PharmD²^*, Abigail Bailey¹^*, Natalie Boytsov, PhD²^*, Emily Luke¹^*, Annabel Lambert¹^* and Cosmina Hogea, PhD³^*

¹Adelphi Real World, Bollington, United Kingdom
²GlaxoSmithKline, Upper Providence, PA
³GlaxoSmithKline (at time of study), Upper Providence, PA

3002

Cost of Disease Progression after Frontline (1L) R-CHOP in Diffuse Large B-Cell Lymphoma (DLBCL)

Rongrong Wang, MPH^*, Josh Roth^*, Carmen Ng^*, Farah Hossain^*, Jia Li and Anthony Masaquel^*

Genentech, Inc., South San Francisco, CA

3003

Cost-Effectiveness of Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axi-cel) for Treatment of Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Christopher Parker, MSc¹^*, Fei Fei Liu, BSc, MBA²^*, Kristen Deger, MS³^*, Conrado Franco-Villalobos, MSc⁴^*, Irina Proskorovsky, M.Sc⁴^*, Scott J Keating, MS²^*, Sonja Sorensen, MPH³^* and Emily Dorman, MPH³^*

¹Bristol Myers Squibb, Uxbridge, United Kingdom
²Bristol Myers Squibb, Princeton, NJ
³Evidence Synthesis, Modeling & Communication, Evidera Inc., Bethesda, MD
⁴Evidence Synthesis, Modeling & Communication, Evidera Inc., Montreal, QC, Canada

3004

Healthcare Resource Utilization and Costs Associated with Obinutuzumab Plus Bendamustine Versus Rituximab Plus Bendamustine for First-Line Treatment of Follicular Lymphoma

Tu My To^*, Jamie T. Ta, PharmD, MS^*, Arpamas Seetasith, PhD^*, Rongrong Wang, MPH^*, Dominic Lai, PharmD^* and Sheila Shapouri, PharmD, MS^*

Genentech, Inc., South San Francisco, CA

3005

Hospitalization for Chemotherapy Toxicities (Chemotoxicities) during Treatment of Pediatric Hematologic Malignancies

Aman Wadhwa, MD, Kathryn Six, MD^*, Smita Bhatia, MD, MPH and Kelly Kenzik, PhD^*

Institute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL

3006

System-Level Barriers to Uptake of Existing and Novel Radioimmunotherapy for People with Lymphoma

Lucy Morgan, MPhil¹^*, Christine Merkel, MSc¹^*, Leo I. Gordon, MD², John Buscombe, MD³^*, Suzanne Wait, PhD¹^*, Martin H. Dreyling, MD, PhD⁴, Erik Mittra, MD, PhD⁵^* and Ajay K Gopal, MD⁶

¹The Health Policy Partnership, London, United Kingdom
²Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Northwestern University, Chicago, IL
³Barts Health NHS Trust, London, United Kingdom
⁴Department of Internal Medicine III, LMU Hospital, Munich, Germany
⁵Oregon Health & Science University, Portland, OR
⁶University of Washington/Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA

3007

An in Depth Analysis of Factors Contributing to Diagnostic Delay in Myeloma: A Retrospective UK Study of Patients Journey from Primary Care to Specialist Secondary Care

Md Imran Hossain¹^*, Peter Hampson²^*, Craig Nowell²^*, Shamshad Khan³^*, Ranjoy Sen¹^*, Sharadha Sundararaman⁴^*, Jagdish Adiyodi¹^* and Supratik Basu⁵^*

¹East Lancashire Hospitals NHS Trust, Burnley, United Kingdom
²The Binding Site, Birmingham, United Kingdom
³Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool, United Kingdom
⁴West Midlands University Hospitals Coventry and Warwickshire, Coventry, United Kingdom
⁵The Royal Wolverhampton NHS Trust, Wolverhampton, United Kingdom

3008

Enhancing Diversity in Oncology Clinical Trials: Findings of a Case Study in Improving Black Patient Representation in a Multiple Myeloma Trial

Sudip Bhandari, PhD¹^*, Charles Lagor, MD, PhD, MBA²^*, Judith Mueller, PhD²^*, Warren Whyte, PhD²^* and Samuel Heilbroner, MD²^*

¹ConcertAI, Baltimore, MD
²ConcertAI, Boston, MA

3009

Feasibility of a Supportive Mobile Health App for Chimeric Antigen Receptor T-Cell Therapy

Rahul Banerjee, MD¹, Bella Sykes, B.S.²^*, Nina Shah, MD¹, Charalambos Andreadis, MD, MSCE¹^*, Peter H. Sayre, MD, PhD¹, Thomas Martin, MD¹, Jason Shore, MBA²^*, Adam Sodowick²^* and Sandy W. Wong, MD³

¹University of California San Francisco, San Francisco, CA
²Patient Discovery Solutions, Inc., Newton, MA
³Department of Medicine, University of California San Francisco, San Francisco, CA

3010

Epidemiology and Predictors of Readmission in CAR T-Cell Therapy Recipients

Aditi Sharma, MD¹^*, Vijendra Singh, MD² and Abhinav Deol²

¹Wayne State University, Detroit, MI
²Karmanos Cancer Institute, Wayne State University, Detroit, MI

3011

Meta-Analysis of Chemotherapy-Induced (Febrile) Neutropenia and Chemotherapy Disruptions Associated with Same-Day Versus Standard (24-72h) Pegfilgrastim Administration in Non-Hodgkin Lymphoma Patients

Neda Alrawashdh, PharmD¹^*, Ali McBride, PharmD, MSc² and Ivo Abraham, PhD, RN³

¹Center for Health Outcomes and Pharmacoeconomic Research, university of arizona, TUCSON, AZ
²Department of Pharmacy Practice and Science, The University of Arizona College of Pharmacy, Tucson, AZ
³Center for Health Outcomes and PharmacoEconomic Research, University of Arizona - College of Pharmacy, Tucson, AZ

3012

A Pilot Study of the Application of Natural Language Interpretation to Identify Insights on Acute Lymphocytic Leukemia and Its Treatment from Social Media Data

Rebecca Crawford, MA¹^*, Verna L Welch, PhD, MPH²^*, Richa Shah, PharmD², Lynda Doward, MRes¹^* and Cheryl Truchan, MBA²^*

¹RTI Health Solutions, Manchester, United Kingdom
²Pfizer Inc., New York, NY

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

902. Health Services Research—Lymphoid Malignancies: Poster II